| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 10/17/2006 | US7122630 Proteins in cell cycle regulation; cell cycle protein binds to SYK kinase |
| 10/17/2006 | US7122629 For forensic analyses, chromosome tissue/cell/organelle-specific markers, production of expression vectors, screening and diagnosis assays |
| 10/17/2006 | US7122624 Peptide for use in the treatment of asthma, emphysema, or other restrictive lung defects |
| 10/17/2006 | US7122623 Compounds and methods for modulating cell adhesion |
| 10/17/2006 | US7122622 Somatostatin analogue as peptide and chelating group covalently linked to N-terminal free amino group of peptide, wherein analogue carries 1-naphthylalanine or 3-benzothienylalanine residue in 3-position; diagnosis |
| 10/17/2006 | US7122621 Contains domains capable of forming amphipathic alpha helix, for cell lysis; site-directed mutagenesis; for treatment of leukemia or stomach carcinoma |
| 10/17/2006 | US7122522 Alpha-fetoprotein peptides and uses thereof |
| 10/17/2006 | US7122521 Collagen mimics |
| 10/17/2006 | US7122520 Nucleotide sequences coding polypeptide for use in the eating disorders |
| 10/17/2006 | US7122517 Crystallized structure of type IV collagen NC1 domain hexamer |
| 10/17/2006 | US7122516 Preparing protease resistant, bioactive amino acid sequences for use as therapeutic peptides; biodrugs; mimetics |
| 10/17/2006 | US7122373 Human genes and gene expression products V |
| 10/17/2006 | US7122372 Peptide useful in immunomodulation |
| 10/17/2006 | US7122363 Comprises nucleotide sequences coding cyclic nucleotide phosphodiesterases for treatment of cardiovascular, depressive and vascular disorders; cardiotonic agents; antidepressants; antihypertensives; antithrombotics |
| 10/17/2006 | US7122354 Therapy for Fabry's disease; genetic engineering; cloning; gene therapy |
| 10/17/2006 | US7122353 For use in cancer therapy |
| 10/17/2006 | US7122352 Expression vectors coding interleukin polypeptide for use in prevention and treatment of infections, autoimmune, and cell proliferative disease and for stimulating the proliferation of platelets; wound healing agents |
| 10/17/2006 | US7122351 Dimerized PDGF-D and materials and methods for producing it |
| 10/17/2006 | US7122350 Promoters provide a sterically repressed promoter in which an additional lac operator site is inserted between the -10 and -35 elements, where it can interfere sterically with binding of RNA Polymerase and thereby prevent the assembly of a poised transcriptional complex |
| 10/17/2006 | US7122349 Human zven proteins |
| 10/17/2006 | US7122348 Adeno-associated viral deletion rep protein comprising functional nuclear localization sequence for use delivery of gene products to preferential intracellular locations |
| 10/17/2006 | US7122347 A chimeric Arterivirus composed of parts originating from at least two different arteriviruses where a stretch of nucleic acids encoding a non-Arteriviris protein fragment is inserted in the full genome; vaccines; veterinary medicine; swine |
| 10/17/2006 | US7122346 Genetic engineering in prokaryotic cells; diagnosis of autoimmune disease using antibodies |
| 10/17/2006 | US7122345 Used to treat blood, brain, urogenital, nervous system, sexual, bone, cardiovascular, gastrointestinal, skin disorders, cancer, bacterial/viral/fungi infections |
| 10/17/2006 | US7122344 Production of recombinant human uteroglobin (rhUG) for use as a therapeutic in the treatment of inflammation and fibrotic diseases. The invention provides processes, including bacterial expression and protein purification and scaled |
| 10/17/2006 | US7122328 For therapy of arthritis |
| 10/17/2006 | US7122327 Utilization of mass spectrometry to elucidate particular biopolymer markers indicative or predictive of a particular disease state, and most particularly to specific biopolymer markers whose up-regulation, down-regulation, or relative presence in disease vs. normal states |
| 10/17/2006 | US7122325 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders |
| 10/17/2006 | US7122324 Vitro methods for determining in vivo thrombotic events |
| 10/17/2006 | US7122318 measuring integrin expression in platelets of a patient to which the drug (especially a sulfonamide) is administered and determining influence of it on integrin expression in cells other than platelets based on the measured expression amount. |
| 10/17/2006 | US7122311 Diagnosing respiratory disorder; obtain cells, monitor expression of marker gene, determine sequence, compare to control, detect polymorphism in polypeptide or nucleotide, presence of polymorphism indicates respiratory disorders |
| 10/17/2006 | US7122306 Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents |
| 10/17/2006 | US7122305 Methods and compositions for identifying receptor effectors |
| 10/17/2006 | US7122302 Method for determining early HCV seroconversion |
| 10/17/2006 | US7122197 Compounds from Moraxella catarrhalis |
| 10/17/2006 | US7122196 Compounds and methods for diagnosis of tuberculosis |
| 10/17/2006 | US7122195 Mutant mycobacteria for use in therapy |
| 10/17/2006 | US7122194 Mixture of polypeptide with carrier |
| 10/17/2006 | US7122193 Comprising peptide analogues which have a half-life which is clearly superior to that of natural proteins or that of synthetic peptides which are or are not derived from these natural proteins |
| 10/17/2006 | US7122192 Porcine circoviruses, vaccines and diagnostic reagents |
| 10/17/2006 | US7122190 Peptide containing amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178, inhibitory of human and nonhuman retroviral, especially HIV, transmission to uninfected cells |
| 10/17/2006 | US7122189 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 10/17/2006 | US7122188 For use in diagnostic method for the detection of infection in humans more particularly the absence or presence of antibodies to proteins of the lymphadenopathy retrovirus (LAV), especially the p18 and/or the p25 proteins |
| 10/17/2006 | US7122184 Monoclonal antibody for use in prevention of fungal infections |
| 10/17/2006 | US7122181 Gene therapy; eye diseases |
| 10/17/2006 | US7122180 DNA vectors containing mutated HIV proviruses |
| 10/17/2006 | US7122179 Live genetically attenuated malaria vaccine |
| 10/17/2006 | CA2342141C Method for detection of legionella bacteria employing purified antigen-specific antibodies |
| 10/17/2006 | CA2293808C Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases |
| 10/17/2006 | CA2212673C Composition and method for generating a foam barrier and methods of use thereof |
| 10/17/2006 | CA2177179C Antagonists to chaperonin 10 |
| 10/12/2006 | WO2006107813A2 Site specific incorporation of phosphoserine into polypeptides using phosphoseryl-trna synthetase |
| 10/12/2006 | WO2006107761A2 Axmi-027, axmi-036 and axmi-038, a family of delta-endotoxin genes and methods for their use |
| 10/12/2006 | WO2006107298A1 Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
| 10/12/2006 | WO2006107183A1 Mussel bioadhesive |
| 10/12/2006 | WO2006106970A1 Process for production of protein having triple-helical structure |
| 10/12/2006 | WO2006106950A1 Novel anti-heparan sulfate antibody, method for detection of heparan sulfate, and kit for detection of heparan sulfate |
| 10/12/2006 | WO2006106912A1 Cancer-associated antigen analog peptide and utilization of the same |
| 10/12/2006 | WO2006106823A1 Method for distinguishing mesenchymal stem cell using molecular marker and use thereof |
| 10/12/2006 | WO2006106678A1 Boron absorption-promoting gene |
| 10/12/2006 | WO2006106521A2 Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
| 10/12/2006 | WO2006106519A2 Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
| 10/12/2006 | WO2006106435A2 Fusion protein comprising a hiv nef double mutant and its use therapy |
| 10/12/2006 | WO2006106193A1 Method for obtaining soluble or better expressed variants of a protein of interest |
| 10/12/2006 | WO2006105998A2 Treatment of cognitive and learning impairment |
| 10/12/2006 | WO2006088664A3 Flavivirus ns5a proteins for the treatment of hiv |
| 10/12/2006 | WO2006085092A3 Methods and uses of antibodies in the purification of interferon |
| 10/12/2006 | WO2006071840A8 Formulations of human growth hormone comprising a non-naturally encoded amino acid |
| 10/12/2006 | WO2006069739A3 Polypeptide species useful for the treatment of neurological disorders |
| 10/12/2006 | WO2006067406B1 Immunomodulatory peptide fragments of cd23 and uses therefor |
| 10/12/2006 | WO2006065137A3 Novel efficient production process for capsular polysaccharides of pathogenic grampositive bacteria by heterologous expression and secretion of complex polysaccharides in non-pathogenic, non-invasive gram- positive bacteria |
| 10/12/2006 | WO2006061217A3 Saquinavir derivatives useful in immunoassay |
| 10/12/2006 | WO2006053743A3 Arabidopsis and brassica nucleic acid sequences conferring lipid and sugar alterations in plants and methods of use |
| 10/12/2006 | WO2006050214A3 Method and system for providing online authentication using biometric data |
| 10/12/2006 | WO2006020717A3 Nucleic acids conferring lipid and sugar alterations in plants ii |
| 10/12/2006 | WO2005117954A3 Compositions and methods for treatment of neovascular diseases |
| 10/12/2006 | WO2005097200A3 Tetanus toxin fusion protein for visualization of active synapses |
| 10/12/2006 | WO2005086695A3 Intracellular interleukin-1 receptor antagonist and uses thereof |
| 10/12/2006 | WO2005086611A3 Methods of precise molecular-level determination of ligand-receptor interactions and designing selective drug compounds based on said interactions |
| 10/12/2006 | WO2005078848A3 Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes |
| 10/12/2006 | WO2005042561A3 Neural regeneration peptides and methods of use |
| 10/12/2006 | WO2005018423A3 Pna oligomers, oligomer sets, methods and kits pertaining to the determination of enterococcus faecalis and other enterococcus species |
| 10/12/2006 | WO2005012479A3 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 10/12/2006 | WO2004112703A3 Interleukin-21 analogs |
| 10/12/2006 | WO2004083389A3 Mbcats as modifiers of the beta-catenin pathway and methods of use |
| 10/12/2006 | WO2004058088A3 Bacteriophage-encoded antibacterial enzyme for the treatment and prevention of gingivitis and root surface caries |
| 10/12/2006 | WO2003097800A3 Cancer-linked gene as target for chemotherapy |
| 10/12/2006 | US20060230471 Expression vector comprising nucleotide sequences coding polypeptides for generation and propagation of drought, freeze and salt resistant plants |
| 10/12/2006 | US20060230470 Promoter expressing foreign gene in root and shoot apex |
| 10/12/2006 | US20060230466 Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof |
| 10/12/2006 | US20060230465 K203 gene and protein |
| 10/12/2006 | US20060229470 Calcium receptor-active molecules |
| 10/12/2006 | US20060229444 Can be used for identifying mu3 opiate receptor agonists and antagonists |
| 10/12/2006 | US20060229436 activation of alpha-lactalbumin comprising contacting (in molten globule-like state) with fatty acids and lipids found in milk fractions containing casein obtained from humans; antibacterial agents; anticancer agents |
| 10/12/2006 | US20060229435 Lymphocyte homing receptors |
| 10/12/2006 | US20060229434 Low-molecular weight peptides inhibiting ion channel activity |
| 10/12/2006 | US20060229433 Modified antiviral peptides with increased activity and cell membrane affinity |
| 10/12/2006 | US20060229432 synthetic vaccine; HIV; multi-antigenic construct comprising carbohydrate antigens linked with polypeptides |
| 10/12/2006 | US20060229273 High affinity oligonucleotide ligands to growth factors |
| 10/12/2006 | US20060229272 or biological fragments in a colon test sample and comparing to that from a normal colon sample, wherein an increased expression level is indicative of gastrointestinal disorders or a predisposition to gastrointestinal disorders |